[Effects of o,p'-DDD on pituitary-gonadal function in patients with Cushing's disease].
O,p'-DDD has a cytotoxic action and inhibits the cholesterol side chain cleavage enzyme, 11 beta-hydroxylase, 3 beta-hydroxysteroid dehydrogenase coupled with delta 5 to 4 isomerase and 21-hydroxylase of the adrenal cells. However, the effects of o,p'-DDD on gonadal steroidogenesis are still unknown. In the present study, the effects of o,p'-DDD on Plasma cortisol, pregnenolone, 17 alpha-hydroxypregnenolone (17-OH-pregnenolone), progesterone, 17 alpha-hydroxyprogesterone (17-OH-progesterone), 11-deoxycorticosterone (DOC), corticosterone, dehydroepiandrosterone (DHEA), delta 4-androstenedione (androstenedione), estradiol, and LH and FSH were investigated in 3 patients with Cushing's disease before and after the administration of o,p'-DDD. The results are presented here. In Case 1 (18 yr old female) who had had secondary amenorrhea for 2 years, the plasma levels of cortisol, pregnenolone, 17-OH-pregnenolone, DHEA, androstenedione, testosterone, estradiol and corticosterone were elevated. The basal levels of plasma LH and FSH and the responses of both gonadotropins were lower than those of women with eumenorrhea. The plasma levels of progesterone, DHEA and testosterone decreased to normal 2 months after the beginning of the administration of o,p'-DDD. She restored menstrual cycles ranging from 40 to 50 days 3 months after the administration of o,p'-DDD, but with anovulatory bleeding. She showed a biphasic body temperature pattern with plasma progesterone and estradiol levels indicating corpus luteum formation 11 months after the start of the treatment, when plasma cortisol as well as progesterone and androgen were reduced to normal. The basal levels of FSH and LH and responses of these gonadotropins were slightly improved at that time. The plasma levels of cortisol, DHEA and androstenedione were high in Case 2 (38 yr old male) and Case 3 (45 yr old male), whereas plasma testosterone level was normal in Case 2 and low in Case 3. The plasma levels of these 3 steroids were normalized 28 days after the beginning of the o,p'-DDD administration. These results suggest that o,p'-DDD does not interfere with gonadal steroidogenesis in Cushing's disease.
Ojima
M
M
Third Department of Internal Medicine, Fukushima Medical College, Japan.
Hashimoto
S
S
Itoh
N
N
Kusano
Y
Y
Satoh
K
K
Egawa
M
M
Gomibuchi
T
T
Fukuchi
S
S
D000293:Adolescent; D000328:Adult; D000728:Androgens / Q000097:blood; D003480:Cushing Syndrome / Q000097:blood / Q000503:physiopathology*; D004967:Estrogens / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D006889:Hydroxycorticosteroids / Q000097:blood; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008875:Middle Aged; D008939:Mitotane / Q000494:pharmacology* / Q000627:therapeutic use; D010053:Ovary / Q000187:drug effects* / Q000378:metabolism; D010902:Pituitary Gland / Q000187:drug effects* / Q000503:physiopathology; D013737:Testis / Q000187:drug effects* / Q000378:metabolism
D000728:Androgens; D004967:Estrogens; D006889:Hydroxycorticosteroids; D008939:Mitotane; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone